TN2009000529A1 - Methods and compositions for treating allergic diseases - Google Patents
Methods and compositions for treating allergic diseasesInfo
- Publication number
- TN2009000529A1 TN2009000529A1 TNP2009000529A TN2009000529A TN2009000529A1 TN 2009000529 A1 TN2009000529 A1 TN 2009000529A1 TN P2009000529 A TNP2009000529 A TN P2009000529A TN 2009000529 A TN2009000529 A TN 2009000529A TN 2009000529 A1 TN2009000529 A1 TN 2009000529A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- compositions
- allergic diseases
- treating allergic
- antibodies
- Prior art date
Links
- 208000026935 allergic disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 abstract 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94520507P | 2007-06-20 | 2007-06-20 | |
| PCT/EP2008/057731 WO2008155365A1 (fr) | 2007-06-20 | 2008-06-18 | Procédés et compositions pour traiter des maladies allergiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000529A1 true TN2009000529A1 (en) | 2011-03-31 |
Family
ID=39846944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000529A TN2009000529A1 (en) | 2007-06-20 | 2009-12-17 | Methods and compositions for treating allergic diseases |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8101182B2 (fr) |
| EP (1) | EP2170957A1 (fr) |
| JP (1) | JP2010530233A (fr) |
| KR (1) | KR20100034015A (fr) |
| CN (1) | CN102027012A (fr) |
| AR (1) | AR067045A1 (fr) |
| AU (1) | AU2008265128A1 (fr) |
| BR (1) | BRPI0813725A2 (fr) |
| CA (1) | CA2691157A1 (fr) |
| CL (1) | CL2008001826A1 (fr) |
| CO (1) | CO6251325A2 (fr) |
| CR (1) | CR11152A (fr) |
| EA (1) | EA201000006A1 (fr) |
| EC (1) | ECSP099812A (fr) |
| IL (1) | IL202573A0 (fr) |
| PE (1) | PE20090768A1 (fr) |
| TN (1) | TN2009000529A1 (fr) |
| TW (1) | TW200918557A (fr) |
| WO (1) | WO2008155365A1 (fr) |
| ZA (1) | ZA200908711B (fr) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1129190E (pt) | 1998-11-13 | 2007-08-08 | Immunex Corp | Adn e polipéptidos de tslp humanos. |
| WO2003032898A2 (fr) | 2001-07-23 | 2003-04-24 | Immunex Corporation | Lymphopoietine thymique stromale (tslp) humaine modifiee |
| EP2222846B1 (fr) * | 2007-08-10 | 2017-05-03 | Protelix, Inc. | Bibliothèques universelles de domaines de liaison de la fibronectine de type iii |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| MX2010008688A (es) * | 2008-02-07 | 2010-08-30 | Schering Corp | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. |
| WO2012007495A1 (fr) * | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Anticorps se liant spécifiquement aux tslpr humains et procédés d'utilisation |
| KR101221649B1 (ko) * | 2010-11-01 | 2013-01-14 | 광주과학기술원 | 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법 |
| LT3031913T (lt) * | 2013-08-09 | 2019-05-27 | Astellas Pharma Inc. | Naujas antikūnas, atpažįstantis žmogaus tslp receptorių |
| MX388536B (es) | 2014-05-07 | 2025-03-20 | Amgen Inc | Autoinyector con elementos reductores del shock. |
| US10156562B2 (en) | 2014-05-16 | 2018-12-18 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| CN106470717B (zh) | 2014-06-03 | 2020-09-11 | 安姆根有限公司 | 药物递送系统和使用方法 |
| MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
| EA033444B1 (ru) | 2014-10-23 | 2019-10-31 | Amgen Inc | Снижение вязкости фармацевтических составов |
| US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
| CA2976935C (fr) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations |
| EP3981450A1 (fr) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille |
| WO2017039786A1 (fr) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Adaptateur d'ensemble de seringue pour une seringue |
| EP3842457A1 (fr) | 2015-09-09 | 2021-06-30 | Novartis AG | Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules |
| AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
| CA3008779A1 (fr) | 2015-12-18 | 2017-06-22 | Astellas Pharma Inc. | Composition pharmaceutique contenant un anticorps anti-recepteur de la tslp humaine |
| US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
| EP4035711B1 (fr) | 2016-03-15 | 2025-06-04 | Amgen Inc. | Réduction de la probabilité de rupture de verre dans des dispositifs d'administration de médicament |
| WO2017189089A1 (fr) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Dispositif d'administration de médicament avec étiquette de messagerie |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
| EP3458988B1 (fr) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée |
| WO2017209899A1 (fr) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments |
| WO2018004842A1 (fr) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (fr) | 2016-10-25 | 2019-09-04 | Amgen Inc. | Injecteur porté sur le corps |
| JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
| AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
| SG11201908058UA (en) | 2017-03-07 | 2019-09-27 | Amgen Inc | Needle insertion by overpressure |
| IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for drug delivery device |
| CN114588404B (zh) | 2017-03-28 | 2024-07-09 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
| AU2018258676B2 (en) | 2017-04-28 | 2024-09-19 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| EP3634539A1 (fr) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Ensemble de seringue d'un appareil d'administration de médicament et procédé d'assemblage |
| MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
| CA3063921A1 (fr) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Dispositif electronique d'administration de medicament comprenant un bouchon active par un ensemble commutateur |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
| MA49677A (fr) | 2017-07-25 | 2021-04-21 | Amgen Inc | Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| WO2019028191A1 (fr) | 2017-08-01 | 2019-02-07 | Amgen Inc. | Systèmes et procédés pour effectuer un dosage du glycane en temps réel d'un échantillon |
| WO2019028187A1 (fr) | 2017-08-01 | 2019-02-07 | Amgen Inc. | Systèmes et procédés de préparation en temps réel d'un échantillon de polypeptide pour analyse par spectrométrie de masse |
| MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
| MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| EP3691717B1 (fr) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
| US11813426B2 (en) | 2017-10-06 | 2023-11-14 | Amgen Inc. | Drug delivery device including seal member for needle of syringe |
| MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
| WO2019090086A1 (fr) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
| CA3079197A1 (fr) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Dispositif d'administration de medicament avec detection de positionnement et de debit |
| US12053618B2 (en) | 2017-11-06 | 2024-08-06 | Amgen Inc. | Fill-finish assemblies and related methods |
| MX2020004736A (es) | 2017-11-10 | 2020-08-13 | Amgen Inc | Embolos para dispositivos de administracion de farmacos. |
| EP3710090A1 (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc. | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
| US12405275B2 (en) | 2018-03-13 | 2025-09-02 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| AU2019234846A1 (en) | 2018-03-13 | 2020-09-24 | Amgen Inc. | Sequential digestion of polypeptides for mass spectrometric analysis |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| KR102682705B1 (ko) * | 2018-07-04 | 2024-07-05 | 고려대학교 세종산학협력단 | 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물 |
| MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
| MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
| WO2020023220A1 (fr) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé |
| WO2020023336A1 (fr) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension |
| MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
| CA3106452A1 (fr) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Systemes et procedes de dosage interventionnel |
| AU2019350660B2 (en) | 2018-09-28 | 2024-09-26 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| MX2021003492A (es) | 2018-10-02 | 2021-06-18 | Amgen Inc | Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna. |
| CA3112214A1 (fr) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Dispositif d'administration de medicament ayant un indicateur de dose |
| SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
| KR20250127186A (ko) | 2018-10-15 | 2025-08-26 | 암젠 인크 | 댐핑 메커니즘을 갖는 약물 전달 장치 |
| IL281908B2 (en) | 2018-11-01 | 2025-06-01 | Amgen Inc | Drug delivery devices with partial drug delivery member retraction |
| MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| EP3894839A1 (fr) | 2018-12-14 | 2021-10-20 | Amgen Inc. | Procédé d'adéquation de système destiné à être utilisé avec une détermination de concentration de protéine par pente |
| EP3924083B1 (fr) | 2019-02-14 | 2024-05-15 | Amgen Inc. | Systèmes et procédés de préparation d'un échantillon et de réalisation d'un dosage en temps réel de l'échantillon |
| CA3127817A1 (fr) | 2019-02-20 | 2020-08-27 | Amgen Inc. | Procedes de determination de la stabilite de proteines |
| AU2020231509A1 (en) | 2019-03-04 | 2021-08-19 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| US12078701B2 (en) | 2019-03-27 | 2024-09-03 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
| CA3137360A1 (fr) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Ensembles et procedes de verification de sterilisation de seringue |
| AU2020286889A1 (en) | 2019-06-04 | 2022-01-20 | Jiangsu Hengrui Medicine Co., Ltd. | Antibody capable of binding to thymic stromal lymphopoietin and use thereof |
| AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| RS66646B1 (sr) | 2019-10-28 | 2025-04-30 | Medimmune Ltd | Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe |
| CN111171150B (zh) * | 2020-02-05 | 2020-12-08 | 北京智仁美博生物科技有限公司 | 抗人tslp抗体及其用途 |
| CA3195365A1 (fr) | 2020-09-18 | 2022-03-24 | Amgen Inc. | Procedes de traitement d'un echantillon pour analyse de cartographie peptidique |
| AU2021376246A1 (en) | 2020-11-05 | 2023-06-08 | Amgen Inc. | Materials and methods for protein processing |
| IL307418A (en) | 2021-05-21 | 2023-12-01 | Amgen Inc | A method for optimizing a filling recipe for a drug container |
| WO2023086793A1 (fr) | 2021-11-09 | 2023-05-19 | Amgen Inc. | Production de protéines thérapeutiques |
| TW202432601A (zh) | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
| WO2024259275A1 (fr) | 2023-06-14 | 2024-12-19 | Bristol-Myers Squibb Company | Quantification en temps quasi réel d'acide sialique de glycoprotéines |
| WO2025101602A1 (fr) | 2023-11-07 | 2025-05-15 | Amgen Inc. | Procédés d'analyse de la teneur en acides aminés d'une protéine thérapeutique |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982990A1 (fr) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Récepteur de cytokine et chaîne de gamma commune similaire |
| US6955895B2 (en) | 2000-06-28 | 2005-10-18 | Whitehead Institute For Biomedical Research | Thymic stromal lymphopoietin receptor molecules and uses thereof |
| ES2391124T3 (es) | 2000-06-28 | 2012-11-21 | Amgen Inc. | Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas |
| US6890734B2 (en) | 2000-11-10 | 2005-05-10 | Schering Corporation | Nucleic acids encoding a cytokine receptor complex |
| EP1487865A4 (fr) | 2002-02-01 | 2005-12-14 | Schering Corp | Utilisations d'une cytokine mammifere et reactifs associes |
| ES2313076T3 (es) * | 2003-07-18 | 2009-03-01 | Schering Corporation | Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica. |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| AU2005277236A1 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| US20060171943A1 (en) | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
| CA2635599C (fr) * | 2006-01-13 | 2014-06-17 | Irm Llc | Procedes et compositions permettant de traiter des maladies alleriques |
| MX2010008688A (es) | 2008-02-07 | 2010-08-30 | Schering Corp | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. |
-
2008
- 2008-06-18 PE PE2008001045A patent/PE20090768A1/es not_active Application Discontinuation
- 2008-06-18 BR BRPI0813725-0A2A patent/BRPI0813725A2/pt not_active IP Right Cessation
- 2008-06-18 KR KR1020107001185A patent/KR20100034015A/ko not_active Ceased
- 2008-06-18 US US12/141,516 patent/US8101182B2/en not_active Expired - Fee Related
- 2008-06-18 WO PCT/EP2008/057731 patent/WO2008155365A1/fr active Application Filing
- 2008-06-18 JP JP2010512681A patent/JP2010530233A/ja active Pending
- 2008-06-18 CN CN2008801025460A patent/CN102027012A/zh active Pending
- 2008-06-18 AR ARP080102594A patent/AR067045A1/es not_active Application Discontinuation
- 2008-06-18 CA CA2691157A patent/CA2691157A1/fr not_active Abandoned
- 2008-06-18 EA EA201000006A patent/EA201000006A1/ru unknown
- 2008-06-18 AU AU2008265128A patent/AU2008265128A1/en not_active Abandoned
- 2008-06-18 EP EP08761179A patent/EP2170957A1/fr not_active Withdrawn
- 2008-06-19 TW TW097122910A patent/TW200918557A/zh unknown
- 2008-06-19 CL CL2008001826A patent/CL2008001826A1/es unknown
-
2009
- 2009-12-07 IL IL202573A patent/IL202573A0/en unknown
- 2009-12-08 ZA ZA200908711A patent/ZA200908711B/xx unknown
- 2009-12-09 CR CR11152A patent/CR11152A/es not_active Application Discontinuation
- 2009-12-17 CO CO09144825A patent/CO6251325A2/es not_active Application Discontinuation
- 2009-12-17 TN TNP2009000529A patent/TN2009000529A1/fr unknown
- 2009-12-18 EC EC2009009812A patent/ECSP099812A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8101182B2 (en) | 2012-01-24 |
| PE20090768A1 (es) | 2009-07-09 |
| WO2008155365A1 (fr) | 2008-12-24 |
| EP2170957A1 (fr) | 2010-04-07 |
| EA201000006A1 (ru) | 2010-10-29 |
| CR11152A (es) | 2010-01-20 |
| BRPI0813725A2 (pt) | 2014-12-30 |
| US20090074747A1 (en) | 2009-03-19 |
| TW200918557A (en) | 2009-05-01 |
| JP2010530233A (ja) | 2010-09-09 |
| CL2008001826A1 (es) | 2009-02-20 |
| AU2008265128A1 (en) | 2008-12-24 |
| ECSP099812A (es) | 2010-01-29 |
| KR20100034015A (ko) | 2010-03-31 |
| CA2691157A1 (fr) | 2008-12-24 |
| CO6251325A2 (es) | 2011-02-21 |
| IL202573A0 (en) | 2011-08-01 |
| CN102027012A (zh) | 2011-04-20 |
| ZA200908711B (en) | 2010-08-25 |
| AR067045A1 (es) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000529A1 (en) | Methods and compositions for treating allergic diseases | |
| TW200736275A (en) | Methods and compositions for treating allergic diseases | |
| PH12013500564A1 (en) | Anti-cd48 antibodies and uses thereof | |
| MY162511A (en) | Engineered anti-tslp antibody | |
| MX2010004327A (es) | Anticuerpos anti-vegf completamente humanos y metodos de uso. | |
| PH12015501806B1 (en) | Novel benzopyran kinase modulators | |
| PH12013500355A1 (en) | Engineered anti-tslp antibody | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
| SG178602A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12012500774A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12012500815A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| MX2012004415A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
| MX2012001262A (es) | Inmunoglobulinas de dominio variable doble y usos de las misma. | |
| MX2011011669A (es) | Inmunoglobulinas de dominio variable dual y usos de las misma. | |
| MX2010008688A (es) | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. | |
| MX338474B (es) | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| PH12015501360A1 (en) | Bmp-6 antibodies | |
| MX357166B (es) | Anticuerpos que se unen a notum pectinacetilesterasa. | |
| AU2014256372B2 (en) | New compositions for treating CMT and related disorders | |
| MX2010003373A (es) | Moduladores de receptores muscarinicos. | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |